Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01723228 · ClinicalTrials.gov registry record · Phase 4
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
A Phase 4 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT01723228: Completed Phase 4 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT01723228 is a Phase 4 study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 170 participants, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01723228, a Phase 4 study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).
Primary Outcome
The SCOPA-COG consists of evaluations in 4 domains: memory, attention, executive functioning, and visuospatial functioning.Scores range from 0 to 43, with higher scores reflecting better performance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rasagiline
Study Locations (20)
Florida
- Teva Investigational Site 015 - Boca Raton
- Teva Investigational Site 021 - Jacksonville
- Teva Investigational Site 033 - Ormond Beach
- Teva Investigational Site 020 - Port Charlotte
- Teva Investigational Site 017 - St. Petersburg
California
- Teva Investigational Site 004 - Irvine
- Teva Investigational Site 016 - La Jolla
- Teva Investigational Site 042 - Long Beach
- Teva Investigational Site 041 - San Bernardino
Connecticut
- Teva Investigational Site 035 - Danbury
- Teva Investigational Site 034 - Manchester
- Teva Investigational Site 037 - New London
Colorado
- Teva Investigational Site 048 - Denver
- Teva Investigational Site 038 - Englewood
Illinois
- Teva Investigational Site 003 - Chicago
- Teva Investigational Site 006 - Chicago
Alabama
- Teva Investigational Site 036 - Birmingham
Arizona
- Teva Investigational Site 047 - Sun City
District of Columbia
- Teva Investigational Site 026 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
What the finished NCT01723228 record still lists
NCT01723228 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01723228 names 20 study sites across 9 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01723228 about?
NCT01723228 is a clinical study titled "Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease". This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).
What is the current status of trial NCT01723228?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 170 participants. The study started on 2012-11. Estimated completion is 2015-01.
What conditions does trial NCT01723228 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01723228?
The interventions under investigation include: Placebo (DRUG), Rasagiline (DRUG).
Who is sponsoring clinical trial NCT01723228?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01723228 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01723228's enrollment target sits among peer trials
170 40th of 158 higher than 119 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
COMPLETED · Phase 4
-
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
COMPLETED · Phase 4
-
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia